Current Report Filing (8-k)
October 09 2018 - 4:17PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
October 9, 2018
(
October 4, 2018)
Heyu
Biological Technology Corporation
(Exact Name of Registrant as Specified in its
Charter)
Nevada
|
|
000-26731
|
|
87-0627910
|
(State or Other Jurisdiction of
Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
4th Floor, No. 10 Building, Xinglin Bay Business
Operation Center,
Jimei District, Xiamen City,
Fujian Province, China 361022
(Address of Principal Executive Offices, Zip
Code)
Registrant’s telephone number, including
area code:
(86) 158 5924 0902
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On
October 4, 2018, the Board of Directors (the “Board”) of Heyu Biological Technology Corporation (the “Company”)
decided to engage in a series of preliminary mergers and acquisitions negotiations under the belief that the best way to develop
the company will be through a merger with, or acquisition of, a business already operating in the bio-technology industry. The
Company identified several target companies and the Board is currently evaluating these targets but the Company does not yet have
an agreement or arrangement to enter into any such merger or acquisition.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Heyu Biological Technology Corporation
|
|
|
|
By:
|
/s/
Ban Siong Ang
|
|
Name:
Title:
|
Ban Siong Ang
Chief
Executive Officer
|
|
|
|
|
|
|
|
Dated:
|
October 9, 2018
|
Heyu Biological Technology (PK) (USOTC:HYBT)
Historical Stock Chart
From Apr 2024 to May 2024
Heyu Biological Technology (PK) (USOTC:HYBT)
Historical Stock Chart
From May 2023 to May 2024